title: Letter to the editor: Hypersensitivity to lamivudine and emtricitabine.
authors.affiliation: Department of Infectious Diseases, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Paris, France. pierre.loulergue@cch.aphp.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Loulergue
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
mesh_terms: D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D000068679:Emtricitabine; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology
chemical_list: D019380:Anti-HIV Agents; D003841:Deoxycytidine; D019259:Lamivudine; D000068679:Emtricitabine